Alterations of p14 ARF , p53 , and p73 Genes Involved in the E2F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma
暂无分享,去创建一个
L. Liotta | J. Herman | J. Jett | W. Travis | Mohammed A. Khan | P. Pairolero | J. Welsh | P. Corn | N. Caporaso | H. Tazelaar | V. Trastek | M. McMenamin | S. Nicholson | N. Okby | C. Harris
[1] W. Kaelin,et al. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation , 2000, Nature.
[2] David I. Smith,et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis , 2000, Nature.
[3] M. Roussel,et al. p53-independent functions of the p19(ARF) tumor suppressor. , 2000, Genes & development.
[4] Erwin G. Van Meir,et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.
[5] R. Jenkins,et al. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. , 2000, American journal of medical genetics.
[6] M. Serrano,et al. The INK4a/ARF locus in murine tumorigenesis. , 2000, Carcinogenesis.
[7] B. Gusterson,et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.
[8] M. Roussel,et al. Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex , 2000, Molecular and Cellular Biology.
[9] R. Sclafani,et al. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein , 2000, Oncogene.
[10] O. Tachibana,et al. Alterations of the INK 4 a / ARF Locus in Human Intracranial Germ Cell Tumors 1 , 2000 .
[11] J. Herman,et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. , 2000, Cancer research.
[12] K. Ichimura,et al. Deregulation of the p 14 ARF / MDM 2 / p 53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G 1S Transition Control Gene Abnormalities 1 , 2000 .
[13] D. Germain,et al. Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins , 1999, Oncogene.
[14] S. Lowe,et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.
[15] J. Haveman,et al. Inactivation of p53 and of pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis , 1999, Journal of Cancer Research and Clinical Oncology.
[16] E. Brambilla,et al. Alterations of expression of Rb, p16INK4A and cyclin D1 in non‐small cell lung carcinoma and their clinical significance , 1999, The Journal of pathology.
[17] J. Herman,et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.
[18] A. Levine,et al. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. H. Randle,et al. Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.
[20] D. Tindall,et al. Mutation and expression analysis of the p73 gene in prostate cancer , 1999, The Prostate.
[21] M. Urioste,et al. Analysis of the INK4a/ARF locus in non-Hodgkin’s lymphomas using two new internal microsatellite markers , 1999, Leukemia.
[22] Toshiaki Tanaka,et al. p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts , 1999, Oncogene.
[23] D. Germain,et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer , 1999, Oncogene.
[24] D. Tindall,et al. Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.
[25] F. McKeon,et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent , 1999, Oncogene.
[26] T. Halazonetis,et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. , 1998, The American journal of pathology.
[27] W. Stolz,et al. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas , 1998, Melanoma research.
[28] M. Tschan,et al. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression , 1998, Oncogene.
[29] C. Sherr,et al. Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.
[30] Karen H. Vousden,et al. p14ARF links the tumour suppressors RB and p53 , 1998, Nature.
[31] J. Benítez,et al. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. , 1998, The American journal of pathology.
[32] Kevin Ryan,et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.
[33] J L Cleveland,et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.
[34] L. Chin,et al. The INK4a/ARF tumor suppressor: one gene--two products--two pathways. , 1998, Trends in biochemical sciences.
[35] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] L. Liotta,et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. , 1998, Cancer research.
[37] Y. Hosokawa,et al. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele‐specific expression , 1998, Genes, chromosomes & cancer.
[38] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[39] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[40] V. Gouyer,et al. Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.
[41] S. Srivastava,et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells , 1998, Oncogene.
[42] L. Liotta,et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. , 1998, Human pathology.
[43] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[44] C. Harris,et al. Serum, plasma and paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes. , 1997, Carcinogenesis.
[45] M. Tucker,et al. Screening for CDKN2A mutations in hereditary melanoma. , 1997, Journal of the National Cancer Institute.
[46] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[47] D. Niewoehner,et al. Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.
[48] G. Peters,et al. Perturbation of cell cycle regulators in human cancer. , 1996, Cancer surveys.
[49] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[50] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[51] S. Tavtigian,et al. Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.
[52] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[53] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[54] J. Jett,et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.
[55] C. D. Edwards,et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.
[56] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[57] R. Hruban,et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.
[58] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[59] M. Skolnick,et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.
[60] D. Sidransky,et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.
[61] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[62] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[63] J. Minna. The molecular biology of lung cancer pathogenesis. , 1993, Chest.
[64] P. Friedman,et al. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.
[65] W. Lee,et al. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.
[66] S. Lowe,et al. The p 53 and p 73 : seeing double ? , 2022 .